Topical hyaluronic acid in the management of oral ulcers

Kapoor, Pranav; Sachdeva, Shabina; Sachdeva, Sonali

doi:10.4103/0019-5154.82485

Cited by 23 publications

(28 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, native high molecular weight hyaluronic acid is anti‐angiogenic and will inhibit blood vessel formation . Topic hyaluronic acid formulations are employed to treat recurrent aphthous ulceration of the oral mucosa with fast symptom relief, to which the dose‐dependent anti‐inflammatory activity of the compound may also contribute.…”

Section: Introductionmentioning

confidence: 99%

Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation

Savarino

Pace

Scarpignato

2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundSeveral studies have shown that patients with non‐erosive reflux disease (NERD) are less responsive to proton pump inhibitors (PPIs) than those with erosive disease as they belong to different subgroups, in whom factors other than acid can trigger symptoms.AimTo evaluate whether combined therapy (mucosal protection plus acid suppression) would improve symptom relief compared to PPI treatment alone.MethodsIn a multicenter, randomised, double‐blind trial, 154 patients with NERD were randomised to receive Esoxx (Alfa Wassermann, Bologna, Italy), a hyaluronic acid‐chondroitin sulphate based bioadhesive formulation, or placebo, in addition to acid suppression with standard dose PPIs for 2 weeks. Symptoms (heartburn, acid regurgitation, retrosternal pain and acid taste in the mouth) and health‐related quality of life (HRQL) were evaluated before and after treatment. The primary endpoint was the proportion of patients with at least a 3‐point reduction in the total symptom score.ResultsAt the end of treatment, the primary endpoint was reached by 52.6% of patients taking Esoxx compared to 32.1% of those given placebo (P < 0.01). The same was true also for HRQL, evaluated by means of the Short Form‐36 questionnaire, which improved with both treatments, but some items were significantly better after Esoxx plus PPI therapy.ConclusionThe synergistic effect of Essox with PPI treatment suggests that mucosal protection added to acid suppression could improve symptoms and HRQL in NERD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation

Savarino

Pace

Scarpignato

2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Clinically, it is largely used for the treatment of several diseases. Topical HA preparations are applied in the management of recurrent aphthous ulceration, with immediate reduction of symptoms due to its barrier effect 2–4…”

Section: Introductionmentioning

confidence: 99%

Barrier effect of Esoxx® on esophageal mucosal damage: experimental study on ex-vivo swine model

Simone¹,

Baldi²,

Vasina³

et al. 2012

CEG

View full text Add to dashboard Cite

The aim of the present study was to assess the potential barrier effect of Esoxx®, a new nonprescription medication under development for the relief of gastroesophageal reflux symptoms. Esoxx is based on a mixture of hyaluronic acid and chondroitin sulfate in a bioadhesive suspension of Lutrol® F 127 polymer (poloxamer 407) which facilitates the product adhesion on the esophageal mucosa. The mucosal damage was induced by 15 to 90 minutes of perfusion with an acidic solution (HCl, pH 1.47) with or without pepsin (2000 U/mL, acidified to pH 2; Sigma-Aldrich). Mucosal esophageal specimens were histologically evaluated and Evans blue dye solution was used to assess the permeability of the swine mucosa after the chemical injury. The results show that: (1) esophageal mucosal damage is related to the perfusion time and to the presence of pepsin, (2) mucosal damage is associated with an increased permeability, documented by an evident Evans blue staining, (3) perfusion with Esoxx is able to reduce the permeability of the injured mucosa, even after saline washing of the swine esophagus. These preliminary results support further clinical studies of Esoxx in the topical treatment of gastroesophageal reflux symptoms.

show abstract

“…acid accelerates wound healing. 9 Hyaluronic acid is a part of the extracellular matrix and is the main glycosaminoglycan secreted during tissue repair. Hyaluronic acid also inhibits fibroblast proliferation.…”

Section: Resultsmentioning

confidence: 99%

“…The current dose is used 3 times daily by applying it to the wound area. 9 Sargassum sp. with concentrations of 50% and 75% are expected to be an alternative therapy for healing traumatic ulcers.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Sargassum sp. ethanolic extract on traumatic ulcers healing in the labial mucosa of Wistar strain (Rattus norvegicus)

2019

View full text Add to dashboard Cite

Introduction:Oral ulcer lesions are one of the most common lesions in the oral cavity. The prevalence of traumatic ulcers is quite high compared to other oral lesions. Brown algae, Sargassum sp. is one of the algae contains flavonoids, vitamin A, vitamin C, iron, and calcium, which play a role in wound healing and has economic value. This study was aimed to determine the effectiveness of Sargassum sp. ethanolic extract on traumatic ulcers healing in the labial mucosa of Wistar strain (Rattus norvegicus). Methods: 28 Wistar strain (Rattus norvegicus) weighed 150-200 grams. The samples were divided into 4 groups (K1, K2, P1, P2); each group consisted of 7 mice. K1 group was administered with Hydroxy Propyl Methyl Cellulose (HPMC), K2 was administered with 0.2% hyaluronic acid gel, P1 was administered with 50% Sargassum sp. extract gel, and P2 was administered with 75% Sargassum sp. extract gel. In each group, the ulcer was made on the mice labial mucosa; then the ulcer diameter was measured and observed on day 1 and day 7. Results: The mean diameter ± standard deviation of traumatic ulcer calculations were K1 (1.09 ± 0.40), K2 (1.81 ± 0.67), P1 (1.39 ± 0.43) and P2 (2.16 ± 0.49) respectively. One way ANOVA test results showed significant differences in K1, K2, P1, and P2 groups. Conclusion: Ethanol extract of Sargassum sp. is effective in accelerating the traumatic ulcers healing at the concentration of 75%.

show abstract

Topical hyaluronic acid in the management of oral ulcers

Cited by 23 publications

References 11 publications

Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation

Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation

Barrier effect of Esoxx® on esophageal mucosal damage: experimental study on ex-vivo swine model

Effectiveness of Sargassum sp. ethanolic extract on traumatic ulcers healing in the labial mucosa of Wistar strain (Rattus norvegicus)

Contact Info

Product

Resources

About

Topical hyaluronic acid in the management of oral ulcers

Cited by 23 publications

References 11 publications

Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation

Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation

Barrier effect of Esoxx&reg; on esophageal mucosal damage: experimental study on ex-vivo swine model

Effectiveness of Sargassum sp. ethanolic extract on traumatic ulcers healing in the labial mucosa of Wistar strain (Rattus norvegicus)

Contact Info

Product

Resources

About

Barrier effect of Esoxx® on esophageal mucosal damage: experimental study on ex-vivo swine model